BioCentury
ARTICLE | Company News

Knopp Biosciences, Prize4Life Inc. neurology news

June 24, 2013 7:00 AM UTC

Knopp will donate de-identified clinical data from 468 patients in the placebo arm in the Phase III EMPOWER trial evaluating dexpramipexole in amyotrophic lateral sclerosis to not-for-profit Prize4Life's PRO-ACT database. Knopp also plans to contribute the treatment arm data from EMPOWER to PRO-ACT following the completion of future dexpramipexole trials in ALS. Prize4Life created PRO-ACT as a freely accessible resource to the global research community. It contains more than 8,600 de-identified unique clinical patient records from 17 late-stage industry and academic trials and over 8 million data points, including 1.7 million records of lab test results from ALS patients. ...